The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Roche says its new assay “resolves this challenge by delivering accurate and specific results
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Akero became a wholly owned subsidiary of Novo Nordisk
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Subscribe To Our Newsletter & Stay Updated
